WASSERBILLIG, Luxembourg — The pjur Group announced today that it has successfully completed its registration with the U.S. Food and Drug Administration (FDA), and received its “Clearance Letter” in July.
The company said that its Quality Management division — under the direction of Patrick Giebel, QM representative and CFO — the entire registration process was completed in just six months due to sound data and excellence in preparation.
With the introduction of polyisoprene and polyurethane condoms, the FDA revised and expanded the registration standards and tests required for personal lubricants. Hence with the latest approvals, pjur’s own formulations meet the new standards by the FDA.
Pjur said that the approval validates the quality standards of its products, considering the strict requirements of the American supervisory authority which is respected and recognized worldwide.
Additional registrations with the Thai FDA were successfully concluded concurrent with the confirmations in the U.S. The pjur Group received the corresponding confirmation from the local supervisory authority last week. With this confirmation, the pjur Group is one of the few companies that can sell personal lubricants registered by the Thai FDA in Thailand.
“Completing the registrations in the U.S. and Thailand within such a short period is an immense success for our company and presents a unique selling opportunity for us. Consumers in the U.S. are following government approvals and compliance more and more as are consumers worldwide. We will benefit greatly from these new seals of approval, again showing the market we are one of highest quality lubricant brands,” Giebel said.
